NIFTP: Key Concepts Regarding Cytology, Surgical Pathology, Molecular Testing and Clinical Practice
N. Paul Ohori MD
Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP) is a new entity that is considered to be a non-malignant but yet an in-situ/dysplastic/pre-malignant process. In this session, we will explore the brief history of follicular-patterned thyroid lesions, biologic nature of NIFTP, the specific histopathologic inclusion and exclusion criteria, cytopathologic issues (e.g. change to the rate of malignancy, effect on the Bethesda System for Reporting Thyroid Cytopathology, and the pre-surgical cytology diagnoses associated with NIFTP), role of molecular testing, and optimal management strategies. Discussions also will include how a successful NIFTP implementation would be effective in reducing overdiagnosis and overtreatment.
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
- Describe the historic background which gave rise to NIFTP.
- Describe the appropriate management for cases suspected of resulting in NIFTP.
- State the reference which provides the histologic criteria for NIFTP.
- Describe the influence of NIFTP on cytology practice.
Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Therefore, it is the policy of the ASC to insure balance, independence, objectivity, and scientific rigor in all its educational programs. All planning individuals participating in any ASC Educational Activity are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. Click here for a complete list.
N. Paul Ohori, MD
The presenter has no conflicts of interest or financial relationships to disclose.
ACCREDITATION AND DESIGNATION STATEMENTS
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Maintenance of Certification (MOC)
This product can help fulfill the CME requirements and Self-Assessment Modules (SAMs) mandated by the American Board of Pathology Maintenance of Certification (MOC) process. Earn up to 2.0 SAM Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the live presentation date.
- 2.00 AMA PRA Category 1 Credit™
- 1.00 California Credits
- 2.00 CMLE
- 2.00 Florida Credits
- 2.00 MOC II
- 2.00 Participant